Gotowa bibliografia na temat „Pharmacokinetics”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Pharmacokinetics”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Pharmacokinetics"
Iorio, Alfonso. "Using pharmacokinetics to individualize hemophilia therapy". Hematology 2017, nr 1 (8.12.2017): 595–604. http://dx.doi.org/10.1182/asheducation-2017.1.595.
Pełny tekst źródłaKamp, Jasper, Erik Olofsen, Thomas K. Henthorn, Monique van Velzen, Marieke Niesters i Albert Dahan. "Ketamine Pharmacokinetics". Anesthesiology 133, nr 6 (30.09.2020): 1192–213. http://dx.doi.org/10.1097/aln.0000000000003577.
Pełny tekst źródłaJeong, Seung-Hyun, Ji-Hun Jang i Yong-Bok Lee. "Pharmacokinetic Comparison between Methotrexate-Loaded Nanoparticles and Nanoemulsions as Hard- and Soft-Type Nanoformulations: A Population Pharmacokinetic Modeling Approach". Pharmaceutics 13, nr 7 (9.07.2021): 1050. http://dx.doi.org/10.3390/pharmaceutics13071050.
Pełny tekst źródłaGrzegorzewski, Jan, Janosch Brandhorst, Kathleen Green, Dimitra Eleftheriadou, Yannick Duport, Florian Barthorscht, Adrian Köller, Danny Yu Jia Ke, Sara De Angelis i Matthias König. "PK-DB: pharmacokinetics database for individualized and stratified computational modeling". Nucleic Acids Research 49, nr D1 (5.11.2020): D1358—D1364. http://dx.doi.org/10.1093/nar/gkaa990.
Pełny tekst źródłaAlbitar, Orwa, Sabariah Noor Harun, Hadzliana Zainal, Baharudin Ibrahim i Siti Maisharah Sheikh Ghadzi. "Population Pharmacokinetics of Clozapine: A Systematic Review". BioMed Research International 2020 (8.01.2020): 1–10. http://dx.doi.org/10.1155/2020/9872936.
Pełny tekst źródłaTang, Bo-Hao, Yue-E. Wu, Chen Kou, Yu-Jie Qi, Hui Qi, Hai-Yan Xu, Stephanie Leroux i in. "Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants". Antimicrobial Agents and Chemotherapy 63, nr 2 (3.12.2018): e02336-18. http://dx.doi.org/10.1128/aac.02336-18.
Pełny tekst źródłaEgan, Talmage D., Bernou Huizinga, Samir K. Gupta, Rudy L. Jaarsma, Richard J. Sperry, James B. Yee i Keith T. Muir. "Remifentanil Pharmacokinetics in Obese versus Lean Patients". Anesthesiology 89, nr 3 (1.09.1998): 562–73. http://dx.doi.org/10.1097/00000542-199809000-00004.
Pełny tekst źródłaStepensky, David. "Pharmacokinetics of Toxin-Derived Peptide Drugs". Toxins 10, nr 11 (20.11.2018): 483. http://dx.doi.org/10.3390/toxins10110483.
Pełny tekst źródłaLi, Qiao, Yan Yang, Ting Zhou, Rui Wang, Na Li, Min Zheng, Yuan-Yuan Li i in. "A Compositive Strategy to Study the Pharmacokinetics of TCMs: Taking Coptidis Rhizoma, and Coptidis Rhizoma-Glycyrrhizae Radix et Rhizoma as Examples". Molecules 23, nr 8 (15.08.2018): 2042. http://dx.doi.org/10.3390/molecules23082042.
Pełny tekst źródłaToja-Camba, Francisco José, Nerea Gesto-Antelo, Olalla Maroñas, Eduardo Echarri Arrieta, Irene Zarra-Ferro, Miguel González-Barcia, Enrique Bandín-Vilar i in. "Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics". Pharmaceutics 13, nr 7 (23.06.2021): 935. http://dx.doi.org/10.3390/pharmaceutics13070935.
Pełny tekst źródłaRozprawy doktorskie na temat "Pharmacokinetics"
Chigutsa, Emmanuel. "Population pharmacokinetics and pharmacokinetic-pharmacodyamic modeling of antitubercular drugs". Doctoral thesis, University of Cape Town, 2013. http://hdl.handle.net/11427/3275.
Pełny tekst źródłaIncludes bibliographical references.
The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in 78 patients with tuberculosis were described using non-linear mixed effects modeling. Pharmacodynamic data was comprised of weekly sputum liquid culture (using mycobacterial growth indicator tubes) time to detection results from 144 patients during the first 2 months of treatment. The effect of drug exposure on patient outcomes was investigated. To determine the adequacy of ofloxacin drug exposure, the probability of attaining the required area-under-the-curve to minimum inhibitory concentration ratio (AUC/MIC) of ofloxacin was determined in 65 patients on treatment for multidrug resistant tuberculosis. To improve efficiency in the clinical development of new drug regimens, clinical trial simulation was used to determine the optimal study design for a study investigating the efficacy of a new antitubercular drug regimen. The SLCO1B1 rs4149032 polymorphism existed at a high frequency of 0.70 in South Africans and resulted in a 28% decrease in bioavailability of rifampicin. The rifampicin peak concentration was a significant predictor of the 2 month treatment outcomes. A semimechanistic time to event model was developed to analyze days to positivity (time to detection) data. The model was comprised of a biexponential decay model describing bacillary decline in sputum from patients, followed by a logistic model with a lag time for growth of the mycobacteria in liquid culture. For the current 800 mg daily dose of ofloxacin, the probability of attaining an AUC/MIC target ratio of at least 100 was only 0.45. Based on clinical trial simulation, the optimum parallel study design was comprised of 125 study participants in each of 2 arms to achieve a study power of at least 80%. Increasing the study length beyond 42 days reduced study power perhaps due to increased amounts of censored data. Higher doses of rifampicin are required in the majority of South African patients with tuberculosis. A novel pharmacodynamic model of tuberculosis treatment is presented, which can be used for investigation of covariates such as drug exposure. Ofloxacin should be replaced with a more potent fluoroquinolone for treatment of multidrug resistant tuberculosis. Clinical trials should not be unduly long otherwise this may compromise study power.
Ulrich-Oppliger, Brigitte Madeleine. "Pharmacokinetics /". Bern, 1992. http://www.ub.unibe.ch/content/bibliotheken_sammlungen/sondersammlungen/dissen_bestellformular/index_ger.html.
Pełny tekst źródłaCharter, Mark Keith. "Maximum entropy pharmacokinetics". Thesis, University of Cambridge, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.316691.
Pełny tekst źródłaSmith, Jennifer Lisa. "Pharmacokinetics of methylamines". Thesis, Massachusetts Institute of Technology, 1992. http://hdl.handle.net/1721.1/12906.
Pełny tekst źródłaKhosravan, Reza. "Nonlinear pharmacokinetics of diltiazem". Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape9/PQDD_0030/NQ46865.pdf.
Pełny tekst źródłaAl-Mustafa, Z. H. "Methotrexate pharmacokinetics and toxicity". Thesis, University of Newcastle Upon Tyne, 1988. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.383988.
Pełny tekst źródłaWoodhouse, Jennifer Ann. "Plutonium pharmacokinetics and blood biochemistry". Thesis, University of Central Lancashire, 1997. http://clok.uclan.ac.uk/20148/.
Pełny tekst źródłaSmith, Adam John. "Modulating the Pharmacokinetics of Bioflavonoids". Scholar Commons, 2012. http://scholarcommons.usf.edu/etd/4226.
Pełny tekst źródłaHarper, Kenneth W. "Pharmacokinetics of methohexitone and midazolam". Thesis, Queen's University Belfast, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.254195.
Pełny tekst źródłaEvans, Gary Lee. "Pharmacokinetics and metabolism of lacidipine". Thesis, University of Hertfordshire, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.387196.
Pełny tekst źródłaKsiążki na temat "Pharmacokinetics"
Pecile, A., i A. Rescigno, red. Pharmacokinetics. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5463-5.
Pełny tekst źródłaRiviere, Jim E. Comparative pharmacokinetics. Chichester, West Sussex: Wiley-Blackwell, 2011.
Znajdź pełny tekst źródłaAmerican Society of Health-System Pharmacists, red. Clinical pharmacokinetics. Bethesda, Maryland: American Society of Health-System Pharmacists, 2012.
Znajdź pełny tekst źródłaKrishna, Devarakonda Rama, i Ulrich Klotz. Clinical Pharmacokinetics. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-75623-8.
Pełny tekst źródłaRiviere, Jim E. Comparative Pharmacokinetics. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9780470959916.
Pełny tekst źródłaDavies, Neal M., i Jaime A. Yáñez, red. FLAVONOID PHARMACOKINETICS. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118468524.
Pełny tekst źródłaWu, Baojian, Danyi Lu i Dong Dong, red. Circadian Pharmacokinetics. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-8807-5.
Pełny tekst źródłaKällén, Anders. Computational pharmacokinetics. Boca Raton, FL: Chapman & Hall/CRC, 2008.
Znajdź pełny tekst źródłaKällén, Anders. Computational pharmacokinetics. Boca Raton: Taylor & Francis, 2007.
Znajdź pełny tekst źródłaMurphy, John E., Pharm. D. i American Society of Health-System Pharmacists., red. Clinical pharmacokinetics. Wyd. 4. Bethesda, MD: American Society of Health-System Pharmacists, 2008.
Znajdź pełny tekst źródłaCzęści książek na temat "Pharmacokinetics"
Gladtke, Erich. "History of Pharmacokinetics". W Pharmacokinetics, 1–9. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5463-5_1.
Pełny tekst źródłaMetzler, Carl M. "Equivalence of Bioavailability and Efficacy in Drug Testing". W Pharmacokinetics, 215–25. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5463-5_10.
Pełny tekst źródłaThakur, Ajit K. "Modeling and Risk Assessment of Carcinogenic Dose-Response". W Pharmacokinetics, 227–44. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5463-5_11.
Pełny tekst źródłaBass, Ludvik, i Susan M. Pond. "The Puzzle of Rates of Cellular Uptake of Protein-Bound Ligands". W Pharmacokinetics, 245–69. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5463-5_12.
Pełny tekst źródłaMordenti, Joyce. "A Pharmacokinetic Equation Guide for Clinicians". W Pharmacokinetics, 271–89. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5463-5_13.
Pełny tekst źródłaWagner, John G. "Pharmacokinetic Studies in Man". W Pharmacokinetics, 291–322. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5463-5_14.
Pełny tekst źródłaBreuer, Francesco. "Metabolic Models in Radiation Protection". W Pharmacokinetics, 323–35. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5463-5_15.
Pełny tekst źródłaBeck, James S. "Conceptual Foundations and Uses of Models in Pharmacokinetics". W Pharmacokinetics, 11–18. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5463-5_2.
Pełny tekst źródłaRescigno, Aldo, i Ajit K. Thakur. "Development of Compartmental Concepts". W Pharmacokinetics, 19–26. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5463-5_3.
Pełny tekst źródłaThakur, Ajit K. "Modeling of Pharmacokinetic Data". W Pharmacokinetics, 27–59. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5463-5_4.
Pełny tekst źródłaStreszczenia konferencji na temat "Pharmacokinetics"
Dol, F., G. Houin, D. Dupouy, C. Caranobe, Y. Cadroy, P. Sié i B. Boneu. "THE PHARMACOKINETICS OF 125-I DERMATAN SULFATE IN THE RABBIT". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643243.
Pełny tekst źródłaEvans, Conor L. "Quantifying human cutaneous pharmacokinetics". W Advanced Chemical Microscopy for Life Science and Translational Medicine 2021, redaktorzy Garth J. Simpson, Ji-Xin Cheng i Wei Min. SPIE, 2021. http://dx.doi.org/10.1117/12.2577713.
Pełny tekst źródłaJohansson, Ann, Jenny Svensson, Stefan Andersson-Engels, Niels Bendsoe, Katarina Svanberg, Irving Bigio, Eleni Alexandratou i in. "mTHPC pharmacokinetics following topical administration". W Biomedical Optics 2006, redaktorzy Gerard L. Coté i Alexander V. Priezzhev. SPIE, 2006. http://dx.doi.org/10.1117/12.647602.
Pełny tekst źródłaCaranobe, C., G. Houin, C. Picard, J. M. Pereillo i B. Boneu. "THE PHARMACOKINETICS OF 125I PENTOSAN POLYSULFATE IN THE RABBIT : EVIDENCE FOR A SATURABLE MECHANISM OF CLEARANCE". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643248.
Pełny tekst źródłaKasyanova, V. V., i I. N. Bazhukova. "Modeling of cerium oxide nanoparticles pharmacokinetics". W THE 2ND INTERNATIONAL CONFERENCE ON PHYSICAL INSTRUMENTATION AND ADVANCED MATERIALS 2019. AIP Publishing, 2020. http://dx.doi.org/10.1063/5.0032208.
Pełny tekst źródłaLee, Seok-Yong, Chang-Keun Cho, Pureum Kang, Eunvin Ko i Chou Yen Mu. "Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict the Pharmacokinetics of Irbesartan in DifferentCYP2C9Genotypes". W ASPET 2023 Annual Meeting Abstracts. American Society for Pharmacology and Experimental Therapeutics, 2023. http://dx.doi.org/10.1124/jpet.122.508580.
Pełny tekst źródłaAhmed, Nusrat, Yashpal S. Chhonker, Valentina Shakhnovich, Veronica Williams i Daryl J. Murry. "Development of a Physiologically Based Pharmacokinetic Model for Predicting Midazolam Pharmacokinetics in a Pediatric Population with Obesity". W ASPET 2024 Annual Meeting Abstract. American Society for Pharmacology and Experimental Therapeutics, 2024. http://dx.doi.org/10.1124/jpet.404.938920.
Pełny tekst źródłaKeith, Godfrey,. "Modelling the Double Peak Phenomenon in Pharmacokinetics". W Modeling and Control in Biomedical Systems, redaktor Rees, Stephen, Chair Andreassen, Steen i Andreassen, Steen. Elsevier, 2009. http://dx.doi.org/10.3182/20090812-3-dk-2006.00022.
Pełny tekst źródłaFeizpour, Amin, Louise Bastholm, Troels T. Marstrand i Conor L. Evans. "Label-free Quantification of Pharmacokinetics in Skin". W Bio-Optics: Design and Application. Washington, D.C.: OSA, 2019. http://dx.doi.org/10.1364/boda.2019.jw3c.1.
Pełny tekst źródłaHovanessian, Vladimir A., Asatour Lalaian i Grigor Gyulkhandanyan. "Laser fluorescence investigation of chlorin e6 pharmacokinetics". W BiOS Europe '96, redaktorzy Stanley B. Brown, Benjamin Ehrenberg i Johan Moan. SPIE, 1996. http://dx.doi.org/10.1117/12.260784.
Pełny tekst źródłaRaporty organizacyjne na temat "Pharmacokinetics"
Hawkins, David R. Determination of Drug Pharmacokinetics and Metabolic Profile. Volume 2. Fort Belvoir, VA: Defense Technical Information Center, marzec 1988. http://dx.doi.org/10.21236/ada192428.
Pełny tekst źródłaHeinen, Jessica. Process of Modeling Pharmacokinetics Using Nonlinear Mixed-Effect Models. Ames (Iowa): Iowa State University, styczeń 2020. http://dx.doi.org/10.31274/cc-20240624-1156.
Pełny tekst źródłaGurley, L. R., K. O. Umbarger, J. M. Kim, E. M. Bradbury i B. E. Lehnert. Staurosporine analysis and its pharmacokinetics in the blood of rats. Office of Scientific and Technical Information (OSTI), lipiec 1994. http://dx.doi.org/10.2172/10160825.
Pełny tekst źródłaCheung, Nai-Kong V., Shakeel Modak, Yukang Lin, Hongfen Guo, Pat Zanzonico, John Chung, Yuting Zuo i in. Pharmacokinetics of Genetically Engineered Antibody Forms Using Positron Emission Tomography. Office of Scientific and Technical Information (OSTI), sierpień 2004. http://dx.doi.org/10.2172/828873.
Pełny tekst źródłaKarna, Shravya, i Alex Konstantatos. Methadone and Buprenorphine for Management of Acute Postoperative Pain. World Federation of Societies of Anaesthesiologists, maj 2022. http://dx.doi.org/10.28923/atotw.472.
Pełny tekst źródłaKamimori, Gary H. Effect of Time of Menstrual Cycle on Drug Pharmacokinetics and Pharmacodynamics. Fort Belvoir, VA: Defense Technical Information Center, maj 2001. http://dx.doi.org/10.21236/ada409105.
Pełny tekst źródłaKornhauser, David M., Brent G. Petty i Paul S. Lietman. Pharmacokinetics and Pharmacodynamics of Sustained Low-Dose Intravenous Infusions of Pyridostigmine. Fort Belvoir, VA: Defense Technical Information Center, maj 1993. http://dx.doi.org/10.21236/ada530411.
Pełny tekst źródłaCarpenter, Hillary M., i Lawrence R. Curtis. Pharmacokinetics of Lipophilic Agents Following Preexposure: Non-Cytochrome P-450 Mediated Mechanisms. Fort Belvoir, VA: Defense Technical Information Center, maj 1990. http://dx.doi.org/10.21236/ada225356.
Pełny tekst źródłaGorden, Patrick J., Michael D. Kleinhenz, Larry W. Wulf, Butch KuKanich, Chang J. Lee, Chong Wang i Johann F. Coetzee. Altered Plasma Pharmacokinetics of Ceftiofur Hydrochloride in Cows Affected with Severe Clinical Mastitis. Ames (Iowa): Iowa State University, styczeń 2016. http://dx.doi.org/10.31274/ans_air-180814-216.
Pełny tekst źródłaLi, Haobo, Zhu Zhang, Haoyi Weng, Yuting Qiu, Pablo Zubiaur, Yu Zhang, Guohui Fan i in. Association of rs2244613 Polymorphism with Dabigatran Pharmacokinetics and Safety: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, czerwiec 2022. http://dx.doi.org/10.37766/inplasy2022.6.0027.
Pełny tekst źródła